2,780
+3.12%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rohto Pharmaceutical Co
Its shares trade on Tokyo Stock Exchange under the ticker 4527.T. It has been listed since 2 October 1961. In the fiscal year to 31 March 2026, it reported revenue of ¥343.73bn and net income of ¥34.25bn. At that date it held total assets of ¥485.77bn and shareholders' equity of ¥301.83bn.
Rohto Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, cosmetics, and functional food items. The company is headquartered in Osaka, Osaka-Fu. The firm primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The firm operates its business in domestic market and overseas markets, including Europe, Asia and America.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Products
- Listed since
- 2 Oct 1961
- Employees
- 6,619
- Website
- rohto.co.jp ↗
Leadership
Pay as last reported
- Mr. Kunio YamadaChairman of the Board, Chief Executive Officer, Chairman of Subsidiary, Representative Director, since 1991¥212.0m
- Mr. Masashi SugimotoPresident, Chief Operating Officer, Chairman of Subsidiary, Representative Director, since 2019
- Mr. Masaya SaitoVice President, Chief Financial Officer, Chairman and President of Subsidiaries, Director, since 2011
- Mr. Yasunori KawasakiChief Human Resource Officer, Director, since 2005
- Mr. Shinichi KunisakiVice President, Chief Technology Officer, Director, since 2010
- Mr. Hidetoshi SegiManaging Director, Chief Strategy Officer, since 2013
- Mr. Yoichi HommaChief Scientific Officer, Director, since 2021
- Ms. Masae YamanakaChief Transformation Officer, Director, since 2024
- Ms. Eriko HayashiIndependent Director
- Mr. Akie IriyamaIndependent Director
- Ms. Maiko KatadaeIndependent Director
- Ms. Haruka MeraIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 51
- Social
- 17
- Governance
- 40
- Direct emissions (scope 1)
- 7,388 t
- Energy emissions (scope 2)
- 5,936 t
- Value chain emissions (scope 3)
- 193,616 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong presence in the pharmaceutical industry, with a broad range of healthcare products and medications.
- Well-established brand reputation and customer trust.
- Robust research and development capabilities, leading to innovative product offerings.
- Extensive distribution network, allowing for widespread availability of products.
Weaknesses
- Limited geographical presence outside of Japan, potentially hindering international growth opportunities.
- Dependence on a few key products, which increases vulnerability to market fluctuations and competition.
- Inconsistent marketing and branding strategies, leading to fragmented messaging.
- Relatively higher production costs compared to some competitors.
Opportunities
- Growing global demand for healthcare products, presenting expansion opportunities in international markets.
- Increasing focus on health and wellness, providing scope for new product development.
- Strategic partnerships and collaborations to enhance research capabilities and market reach.
- The rise of e-commerce platforms, enabling direct-to-consumer sales and improved accessibility.
Threats
- Intense competition within the pharmaceutical industry, with both domestic and international players.
- Stringent regulations and compliance requirements, increasing operational costs and time-to-market.
- Potential impact of adverse events and product recalls on the company's reputation and financial stability.
- Economic uncertainties and fluctuations affecting consumer spending patterns.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.